8 Nov 2021
GRAFTYS SA (Belgium) announces acquisition of French company Biologics4Life along with new equity investment of $3M (2.6M€)
Graftys SA, a company specialized in the design and manufacture of bone graft substitutes for orthopedic surgery, announces its acquisition of Biologics4Life, a French company which is developing a new generation of injectable synthetic bone graft materials. To achieve its new development and commercial ambitions, Graftys raised $3M from Go Capital via its Ouest Venture 3 fund along with Noshaq and other European investors. This fundraising will be complemented with investment from Belgian, French and other European public subsidies.
Graftys is an innovative company headquartered in Belgium, with a subsidiary in France (Aix-en-Provence). The firm manufactures a range of first-in-class resorbable calcium phosphate cement in its ISO certified facilities. Its innovative products are commercialized in over 25 countries (including US and Brazil) with clearance from FDA, CDMAS, Anvisa and European notified body. Revenues in 2021 reached several million Euros.
Biologics 4 life is an early stage company committed to the design and development of advanced biomaterial technologies to treat bone metabolic disorders. Their focus has been on combination materials including active principles for treatment of osteoporotic fractures and bone metastases.
Graftys’ acquisition of Biologics4Life will build its expertise in bone graft and in advanced treatment for patients suffering from fracture or bone loss. The combination will strengthen cross-functional capabilities in R&D, manufacturing, regulatory affairs, and global commercialization.
Aurélien Valet & Sébastien Genesta, former Managing Directors at Biologics4Life, will assume executive roles in the management of Graftys, supported by their CFO, Xavier Ferry. The Board of Directors of Graftys SA will be partially renewed and reinforced.
« After three years of intensive product development work, we are pleased to join Graftys and its financial partners to greatly accelerate R&D, clinical work, and commercialization of our technology, » said Aurelien Valet and Sébastien Genesta, co-founders of Biologics4Life.
« The advanced product development, the excellent quality of academic and medical partnerships as well as the reputations of Biologics4Life’ founders in the bone substitute field have convinced GO CAPITAL to reinvest in Graftys and to complete the acquisition of Biologics4Life. The combined organization provides a very strong platform for future development. » said Bruno Guicheux, Investment Director at GO CAPITAL.
*About GO CAPITAL
GO CAPITAL, an independent management company, is a key player in seed capital and risk capital in the regions. Based in Brittany, Pays de la Loire, Normandy, Centre Val de Loire and Région Sud, GO CAPITAL helps finance responsible innovation across the regions. Its team is made up of investors with complementary sectoral experience, and has a solid track record in deep tech. With more than 130 investments to its credit, GO CAPITAL manages more than €200M and mainly finances technology leaders in the digital, healthcare and future industry (energy transition, maritime economy, agri-agro, etc.) sectors.
More info : https://www.gocapital.fr/
**About The Innovation Fund
Created in February 2015, Innovation Fund invests in innovative startups and companies active in the field of chemistry and life sciences. The fund has a capital of €35m, financed by more than 50% by major companies in the sector, bringing unique industrial support value to the investment projects. The remaining 50% is held by national and regional investment funds, universities, banks and individuals. To date, the Innovation Fund has already invested in 352 companies.
More info: http://www.innovationfund.eu
*** About Noshaq
Noshaq is an investment fund with a portfolio of 474 companies, including over 85 companies in the life sciences. Noshaq is the reference financial partner for the creation and development of SMEs in the Liège region. Over the years, Noshaq has developed a range of financing vehicles, which are suited to market needs and trends, as well as its strategy. Every service provided by Noshaq (capital – loans – leasing) is always designed according to the requirements and needs of the owner-investor. The aim is always to have a lever effect on the company’s development. https://www.noshaq.be/
Graftys and Biologics4Life : Aurélien VALET – General Manager of the Graftys Group – +33 6 27 46 22 15
USA : Ron Lowell, Business Development +1 847 651 3723
GO CAPITAL : Bruno GUICHEUX – Investment Director – +33 6 84 98 58 96
The Innovation Fund : André OSTACHKOV – Investment Director – +32 499 67 47 04
Noshaq : Benoit FELLIN – Investment Director – +32 473 84 11 59